Recommendations, evidence and sustainability of screening for pancreatic cancer in high-risk individuals
- PMID: 40210328
- DOI: 10.1016/j.bpg.2025.101974
Recommendations, evidence and sustainability of screening for pancreatic cancer in high-risk individuals
Abstract
Pancreatic cancer is a highly lethal malignancy and is predicted to become the second leading cause of cancer-related deaths by 2030. Early detection significantly improves outcomes, but general population screening remains infeasible due to the low prevalence of the disease and lack of specific biomarkers. This review evaluates current recommendations for pancreatic cancer surveillance in high-risk individuals, synthesises evidence from recent studies and explores the sustainability of current imaging-based surveillance programmes. Challenges such as overdiagnosis, economic feasibility and disparities in access highlight the need for targeted, cost-effective strategies. Collaborative initiatives and consortia are needed to advance biomarker research and refine risk stratification. By integrating evidence-based recommendations with sustainable approaches, this review outlines pathways to improve early detection and reduce mortality from pancreatic cancer.
Keywords: Early detection; High-risk individuals; Pancreatic cancer; Screening; Surveillance.
Copyright © 2025. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of competing interest Aleksander M. Bogdanski: none. Pilar Acedo: none. Michael B. Wallace: Consulting: Boston Scientific, ClearNote Health, Cosmo Pharmaceuticals, Endostart, Endiatix, Fujifilm, Medtronic, Surgical Automations, Ohelio Ltd, Venn Bioscience; Research grants: Fujifilm, Boston Scientific, Olympus, Medtronic, Ninepoint Medical, Cosmo/Aries Pharmaceuticals; Stock/Stock Options:, Virgo Inc., Surgical Automation; Consulting on behalf of Mayo Clinic: Boston Scientific. Microtek. Monique E. van Leerdam: none. Derk C.F. Klatte: none.
Similar articles
-
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.World J Gastroenterol. 2018 Nov 21;24(43):4846-4861. doi: 10.3748/wjg.v24.i43.4846. World J Gastroenterol. 2018. PMID: 30487695 Free PMC article. Review.
-
Principles of Cancer Screening.Surg Clin North Am. 2015 Oct;95(5):953-66. doi: 10.1016/j.suc.2015.05.009. Epub 2015 Jun 20. Surg Clin North Am. 2015. PMID: 26315516 Free PMC article. Review.
-
Cost-effectiveness of Pancreatic Cancer Surveillance in High-Risk Individuals: An Economic Analysis.Pancreas. 2019 Apr;48(4):526-536. doi: 10.1097/MPA.0000000000001268. Pancreas. 2019. PMID: 30946242
-
Screening for pancreatic cancer: a review for general clinicians.Rom J Intern Med. 2020 Sep 1;58(3):119-128. doi: 10.2478/rjim-2020-0009. Rom J Intern Med. 2020. PMID: 32364522 Review.
-
AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.Gastroenterology. 2020 Jul;159(1):358-362. doi: 10.1053/j.gastro.2020.03.088. Epub 2020 May 19. Gastroenterology. 2020. PMID: 32416142 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical